Patient characteristics and treatment
MM, Relapsed, stage IA.Includes stage IIA, PD, MR
MULTIPLE MYELOMA, MINOR, DISEASE, ONCOLOGY, MYELOMA
A total of 39 patients were enrolled between June 2014 and August 2018. Of these, 36 patients were treated at three dose levels: eight at DL1 (plitidepsin 4.0 mg/mOf the 39 enrolled patients at all dose levels, with median age 66 years (range, 51–80 years), 19 (49%) had previously received hematopoietic stem cell transplantation (HSCT) (12 patients, 44%, at the RD) (Table Baseline characteristics of included patientsAbbreviations: BTZ, bortezomib; CR, complete response; ECOG, Eastern Cooperative Oncology Group; HSCT, hematopoietic stem cell transplantation; Ig, immunoglobulin; IMiDs, immunomodulatory; ISS, International Staging System; MM, multiple myeloma; MR, minor response; PD, progressive disease; PR, partial response; RD, recommended dose; SD, stable disease; UK, unknown; VGPR, very good partial response.All stage IA.Includes stage IIA (Includes stage IIIA (Relapsed MM: previously treated myeloma that progressed and required salvage therapy but did not meet the criteria for either “refractory” or “relapsed and refractory” myeloma. Total refractory MM includes both, “refractory MM” and “relapsed and refractory MM”. A total of 227 cycles were administered at all dose levels (median of 3 cycles per patient, range, 1–29 cycles); 111 of these cycles were given at the RD cohort, with a median of 2 cycles per patient (range, 1–29 cycles). Median relative dose intensity at the RD was 73% for both plitidepsin and BTZ, and 68% for DXM.